42 results about "Bladder tumor" patented technology

The invention discloses a semi-supervised bladder tumor medical image segmentation method based on supervised branches and uncertainty estimation, and relates to the technical field of bladder tumor medical image segmentation. Comprising the following steps: S1, acquiring data; s2, data preprocessing; s3, data division; s4, constructing a model; s5, performing model training; and S6, carrying out segmentation identification. The invention provides a new semi-supervised task method, which introduces a supervision branch, combines a pseudo tag and uncertainty estimation based on information entropy, uses an average teacher model as a bottom layer architecture, and provides a supervision signal through a prediction result of a supervision branch network. Therefore, the bladder tumor segmentation model is supervised to generate a more accurate segmentation result.

The invention discloses a bladder cancer individualized diagnosis and treatment method based on multi-modal magnetic resonance image fusion and a related device. The method comprises the following steps: acquiring multi-modal image data of a bladder tumor of a patient; extracting quantitative image features related to staging and grading of the bladder cancer according to the multi-modal image data; dynamic curve characteristics of dynamic contrast enhanced magnetic resonance imaging DCE-MRI are extracted according to the quantitative image characteristics, the dynamic curve characteristics comprise a rising slope, peak arrival time and an area under a curve AUC, and heterogeneity of the dynamic curve characteristics in different areas of the bladder cancer tumor is analyzed to form a DCE-MRI characteristic set; the muscle layer infiltration depth and range of the bladder cancer tumor and the surrounding tissue invasion condition are quantitatively evaluated, and the individualized resection depth and range and the operation method of the transurethral bladder tumor are predicted. According to the method, the multi-modal magnetic resonance images are fused, the quantitative image features and the dynamic curve features are extracted, the muscle layer infiltration depth and the surrounding tissue invasion condition of the bladder cancer tumor are quantitatively evaluated, and an individualized diagnosis and treatment scheme is achieved.

The application discloses a bladder tumor specimen extractor which comprises an adjusting transmission assembly capable of controlling preliminary cutting, a separating assembly capable of separating a tissue part and a liquid part of the bladder tumor and an operating handle. The application belongs to the technical field of bladder tumor surgery. When the bladder tumor temporarily stays on a tissue liquid passing layer, the removed bladder tumor can be punctured by a plurality of groups of puncture heads, so that the tissue part of the bladder tumor is blocked by the tissue liquid passing layer, and the tissue liquid and the plasma part of the bladder tumor can pass through the tissue liquid passing layer and enter a liquid storage bag. After sampling is completed, medical staff can take out the liquid storage bag to sample the tissue liquid and the plasma part of the bladder tumor, and the tissue part of the bladder tumor can be sampled from the tissue liquid passing layer. The application provides a brand-new bladder tumor sampling experience, greatly reduces the possibility of tissue liquid and plasma remaining in the bladder and brings convenience to medical staff.

The application relates to the field of biological preparations, and particularly discloses an immunochromatographic reagent for detecting malignant tumors in urine and application thereof, which is used for solving the problems of poor recognition of tumor specific epitopes, heavy background interference, spectrum overlap and high subjectivity of artificial judgment in the single staining and color development of acridine orange in the detection of urinary exfoliative cells of bladder cancer. The color development reagent comprises A reagent, B reagent, C reagent and D reagent. The A reagent is provided with an antibody complex for target antigens of bladder tumor cells in urine exfoliation and acridine orange. The B reagent comprises a fluorescently labeled secondary antibody composition corresponding to the A reagent and an enzyme-labeled secondary antibody-tyramide deposition amplification composition. In the application, AI imaging analysis is adopted to calibrate layered recognition labels and acridine orange staining negative and positive labels. Through multi-target immunochromatography, two sets of color separation amplification schemes and AI imaging analysis, the application improves the recognition ability of bladder tumor specific epitopes, the image quality and the image analysis accuracy in the detection of urinary exfoliative cells.

The utility model relates to the technical field of bladder tumor treatment in urinary surgery, and discloses a device for taking out a whole block of bladder tumor after enucleation, which comprises a hollow long tube, a plurality of U-shaped long sheets are fixedly connected to the periphery of the outer wall of the hollow long tube at equal intervals, and a second connecting rod is rotatably connected to the inside of each U-shaped long sheet. An H-shaped block is rotationally connected to the top of the second connecting rod, a first connecting rod is rotationally connected to the upper middle portion of the inner wall of the H-shaped block, a U-shaped short piece is rotationally connected to the outer wall of the first connecting rod, and a hollow bottom block is fixedly connected to the outer wall of the U-shaped short piece. According to the anesthesia device, the first connecting rod in the U-shaped short piece, the H-shaped block and the second connecting rod on the lower middle portion of the inner wall rotate outwards and extrude to move and release force, and therefore the problem that after the hands of medical staff and the body of an anesthetized patient slightly move, the body of the patient is harmed after the anesthesia device is taken out is solved.

The invention belongs to the field of intelligent medical treatment, and particularly relates to a bladder tumor image segmentation method and device, a medium and a program product. The method comprises the following steps: S101, acquiring an image of a bladder tumor patient; s102, inputting the image into a 2D U-Net for tumor segmentation to obtain a 2D segmentation result; s103, traversing the shape of the tumor based on the 2D segmentation result, inputting the image into 3D U-Net for tumor segmentation to obtain a 3D segmentation result if the shape of the current tumor is regular during traversing, and taking the segmentation result of the current tumor in the 3D segmentation result; if the tumor shape is irregular, the segmentation result of the current tumor in the 2D segmentation result is obtained, and after traversal is completed, the segmentation results of the multiple tumors are output after merging. Through the hybrid 2D-3D method, the segmentation performance can be optimized by using the complementary advantages of the two methods, and a better segmentation result is obtained.

The invention provides a sorbitol and mannitol flushing fluid for urinary surgery. The invention relates to a freeze-dried powder injection, which comprises 20 to 50 grams of sorbitol, 10 to 30 grams of mannitol, 5 to 10 grams of sodium bicarbonate and 0.5 to 2 grams of sodium citrate in every 1000 milliliters of the freeze-dried powder injection, and the pH value of the freeze-dried powder injection is adjusted to 7.2 to 7.4. The preparation method comprises the following steps: heating distilled water to 80 DEG C, sequentially adding the components, continuously stirring until the components are completely dissolved, cooling to room temperature, fixing the volume to 1000ml, adjusting the pH value by using a 5mol / L sodium hydroxide solution, finally sterilizing by using a 0.22-micron microporous filter membrane, and packaging in a sterilized glass bottle. The flushing fluid can effectively dissolve blood clots, stones and necrotic tissues in an operation field by utilizing the high osmotic pressure characteristics of the sorbitol and the mannitol, so that the operation field is kept clear. The flushing fluid disclosed by the invention shows an excellent flushing effect and good safety in urinary surgery operations such as transurethral bladder tumor electrocision, flexible ureteroscope calculus removal and the like.

1. Name of the design product: Bladder Floater. 2. Use of the design product: It can be equipped with a hyperthermia modular component (Design 1) or a drug release modular component (Design 2) to achieve regular hyperthermia for bladder tumors or multiple, timed, and quantitative bladder drug release functions respectively, avoiding repeated, long-term, and invasive catheterization operations. 3. Design key points of the design product: Lies in the shape. 4. Picture or photo that best shows the design key points: Perspective view of Design 1. 5. The rear view of Design 1 is the same as the front view of Design 1, so the rear view of Design 1 is omitted; the right view of Design 1 is the same as the left view of Design 1, so the right view of Design 1 is omitted; the rear view of Design 2 is the same as the front view of Design 2, so the rear view of Design 2 is omitted; the right view of Design 2 is the same as the left view of Design 2, so the right view of Design 2 is omitted. 6. Design 1 is designated as the basic design.

This invention belongs to the field of molecular biology and medical detection technology, and discloses a bladder cancer-specific nucleic acid aptamer, nucleic acid aptamer derivatives, and their applications. The nucleotide sequences of the nucleic acid aptamer are shown in SEQ ID NO: 1, 2, and 3. This invention screened three monoclonal nucleic acid aptamer DNA chains from bladder cancer tissue samples using the exponential enrichment systematic evolution (SELEX) technique and identified two target proteins that bind to these three nucleic acid aptamers. The nucleic acid aptamers specifically target the target proteins CAPRIN1 and FXR1 on the surface of bladder tumor cells. The nucleic acid aptamers obtained by this invention have advantages such as high affinity and specificity, no immunogenicity, simple chemical synthesis, stability, and ease of storage and labeling, providing a new molecular tool for the early diagnosis and targeted therapy of bladder cancer.

The present invention relates to a method for providing information for predicting the likelihood of bladder cancer recurrence, which provides information that patients who have undergone transurethral resection of a bladder tumor and test positive for suspicious high-grade urothelial carcinoma (SHGUC) or high-grade urothelial carcinoma (HGUC) in a urine cytology test have a higher likelihood of bladder cancer recurrence compared with patients who do not test positive.

The invention discloses a bladder tumor cell strain with squamous differentiation characteristics and application thereof, and relates to the technical field of biological medicines. Wherein the bladder tumor cell strain is selected from one of a human bladder tumor cell strain MP-MGHU3-LT, a human bladder tumor cell strain UCSD-MGHU3-LT, a human bladder tumor cell strain UCSD-RT4-LT and a mouse bladder tumor cell strain mUCMP, the bladder tumor cell strains are all preserved in the China Center for Type Culture Collection, and the preservation numbers of the bladder tumor cell strains are respectively CCTCC NO: C2025241, CCTCC NO: C2025252, CCTCC NO: C2025253 and CCTCC NO: C2025254. The bladder tumor cell strain provided by the invention has squamous differentiation characteristics, and can be applied to model construction, mechanism research and drug screening of bladder cancer with squamous differentiation characteristics.

The invention relates to the field of bladder irrigation, and particularly discloses a visual irrigation device for bladder tumor electric resection, which is arranged at one end of a catheter to communicate the catheter with a bladder. Comprising a cylinder with a piston cavity; the bin body is provided with a cavity; the connecting piece is fixedly arranged at one end of the conduit; the piston is slidably arranged in the piston cavity; the sieving assembly is arranged in the cavity to filter tumor tissues; wherein an endoscope is arranged on the catheter to observe the internal condition of the bladder; the connector is provided with a connector inserted into a catheter orifice to be communicated with a catheter; the bin body is arranged on the cylinder body and is inserted into the connecting piece together with one end of the cylinder body to form fixation; a first one-way valve communicated with the cavity and a second one-way valve communicated with the piston cavity are arranged in the connecting piece; the opposite parts of the inner wall of the piston cavity and the inner wall of the cavity form a communicating port to communicate the piston cavity with the cavity; the flushing device for the visual bladder tumor electric resection operation has the beneficial effect that the flushing device for the visual bladder tumor electric resection operation has the screening function.

This invention discloses a bladder tumor segmentation method and system based on parallel branch-focused linear attention, belonging to the field of bladder tumor segmentation technology. The method includes: a main branch extracting specific morphological and structural features from cystoscopy images, combined with a novel focused linear attention module to achieve high efficiency and expressiveness; a fast convolutional branch capturing spatial details to compensate for the limitations of the main branch in full-size prediction; a spatial channel reconstruction convolutional residual module reducing redundant computation and promoting representative feature learning, thus lowering complexity and computational cost; and a prediction head connecting the main branch and the fast convolutional branch, fusing the coarse-grained features extracted by the main branch with the fine-grained features extracted by the fast convolutional branch to predict the segmentation map. This invention improves the morphological specificity of bladder tumors, the distinction between bladder tumors and normal tissues, and the problem of blurred bladder tumor boundaries, significantly improving computational efficiency.

The invention discloses a bladder tumor specimen extractor which comprises an adjusting transmission assembly capable of controlling preliminary dicing, a separating assembly capable of separating a tissue part and a liquid part of a bladder tumor and an operating handle. The invention belongs to the technical field of bladder tumor surgery. When the bladder tumor temporarily exists on the tissue fluid passing layer, the puncture heads can puncture the taken-down bladder tumor, so that the tissue part of the bladder tumor is blocked through the tissue fluid passing layer, and the tissue fluid and plasma part of the bladder tumor can penetrate through the tissue fluid passing layer and enter the fluid storage bag; medical staff can sample tissue fluid and plasma parts of the bladder tumor by taking down the fluid storage bag, the tissue part of the bladder tumor can be sampled from the tissue fluid passing layer, brand-new bladder tumor sampling experience is provided, the possibility that the tissue fluid and the plasma are left in the bladder is greatly reduced, and convenience is brought to the medical staff.

The invention provides application of quercetin in preparation of a medicine for regulating intestinal microbiological disorder caused by bladder cancer, and belongs to the technical field of medical technology. It is found for the first time that quercetin regulates intestinal flora in the occurrence and development process of bladder cancer, effectively enriches tumor-related intestinal beneficial bacteria, can reverse disorder of in-vivo metabolic markers and reduces the level of L-serine, and therefore the effect of inhibiting the progress of bladder tumor is achieved.

The invention belongs to the technical field of biological medicines, and particularly relates to a bladder cancer targeted nano-drug and a preparation method thereof. The drug is constructed by taking a chemotherapeutic drug gemcitabine-loaded poly (lactic-co-glycolic acid) nanoparticle as a core and assembling two functional components, namely a gadolinium-doped zinc-aluminum layered double hydroxide folic acid conjugate and a bismuth-tellurium alloy nano-cluster hyaluronic acid compound, on the surface of the nanoparticle. During preparation, the drug-loaded nanoparticles are prepared by adopting a multiple emulsion solvent evaporation method, and then the two functional compounds are co-assembled on the surfaces of the drug-loaded nanoparticles by utilizing electrostatic interaction to form the multifunctional hybrid shell layer. The nano-drug integrates multiple functions such as active targeting, microenvironment response drug release, multi-mode imaging, chemotherapy and chemical kinetics combined treatment and radiotherapy sensitization, enrichment and permeation of the drug at a bladder tumor part can be remarkably improved, efficient synergistic treatment is achieved, system toxicity is reduced, and the nano-drug is particularly suitable for perfusion treatment in the bladder.

This invention discloses a bladder tumor image segmentation method and system based on FEBE-Net, applied in the field of image processing technology. The invention employs a PVTv2 encoder to learn multi-scale feature representations to adapt to variations in bladder tumor size and shape. Secondly, a feature exploration attention module is proposed to fully mine potential local details in the shallow features extracted by the PVTv2 encoder and eliminate noise, supplementing missing fine-grained details for the decoding stage and improving network segmentation performance. Simultaneously, a boundary enhancement and refinement (BER) module is proposed, which uses a boundary detection operator to additionally learn the boundaries of the bladder tumor to enhance the boundary regions in the input features of the decoder and refine the final predicted feature map. Finally, an efficient self-attention calibration decoder module is proposed, which, with the help of boundary cues provided by the BER module, gradually and effectively recovers global contextual information and local detail information from high-level and low-level features.

The application belongs to the field of molecular biology and medical detection technology, and discloses a bladder cancer nucleic acid aptamer, a nucleic acid aptamer derivative and application thereof.The nucleotide sequence of the nucleic acid aptamer is shown as SEQ ID NO:6.Through an exponential enrichment system evolution (SELEX) technology, a single clone nucleic acid aptamer DNA chain of a bladder cancer tissue sample is screened, and two target proteins targeted and combined with the nucleic acid aptamer are identified.The nucleic acid aptamer can specifically target the target proteins CAPRIN1 and FXR1 on the surface of bladder tumor cells.The nucleic acid aptamer screened in the application has the advantages of high affinity and specificity, no immunogenicity, simple chemical synthesis, stability, easy preservation and labeling, and the like, and provides a new molecular tool for early diagnosis and targeted treatment of bladder cancer.

Provided herein are methods and systems for cancer detection and monitoring. The methods may include minimal residual disease analysis. The methods may include using nucleic acids from a urine sample or a urine cell pellet sample. The methods may include assaying nucleic acids in urine to detect a set of biomarkers from the sample. The methods may include monitoring a subject after transurethral bladder tumor resection.

The application belongs to the field of intelligent medical treatment, and particularly relates to a bladder tumor image segmentation method, device, medium and program product. The method comprises the following steps: S101, acquiring an image of a bladder tumor patient; S102, inputting the image into a 2D U-Net for tumor segmentation to obtain a 2D segmentation result; S103, based on the 2D segmentation result, traversing the shape of the tumor, if the current tumor shape is regular, inputting the image into a 3D U-Net for tumor segmentation to obtain a 3D segmentation result, and taking the segmentation result of the current tumor in the 3D segmentation result; if the tumor shape is irregular, taking the segmentation result of the current tumor in the 2D segmentation result, and after the traversal is completed, merging and outputting the segmentation results of multiple tumors. The application can optimize the segmentation performance by using the complementary advantages of the 2D-3D method, and obtain better segmentation results.

The invention discloses a targeted drug delivery system in a bladder. The targeted drug delivery system comprises a reagent A and a reagent B, the reagent A is a biological micromotor, platelets are taken as a natural carrier, and streptavidin is bridged and coupled with biotinylation modified urease to serve as a driving component to entrap active components; the reagent B is a urea solution. According to the invention, the natural characteristics of platelet chemotaxis tumor inflammation microenvironment are utilized to realize specific enrichment of motors in a bladder tumor area; after urea perfusion, urease catalyzes urea to generate gas power to push the motor to move, meanwhile, compact extracellular matrixes are slightly loosened, the motor is assisted to penetrate and reach the interior of a tumor and release drugs, and the delivery efficiency and targeting performance of the drugs in the bladder are remarkably improved.

Some embodiments of the present disclosure are directed to methods and compositions for the treatment of tumors, using a combination of immunotherapeutic agents and tumor-targeting viral capsid protein assemblages comprising anti-cancer molecules conjugated to viral capsid proteins.

The invention provides a solution to deficiencies in innate immune cell targeting in solid tumors, including bladder cancer, through IL-18 or IL-15 Tetra protein targeted Killer Engagers (TetraKEs). These leverage CD16 and CD56 to enhance natural killer (NK) cell targeting of Nectin-4+ bladder tumor cells, offering a novel immunotherapeutic approach.

The application provides a freezing device and a lithotripsy device. The freezing device is used for freezing a calculus or a bladder tumor. The freezing device comprises a main machine, a freezing catheter and a freezing head. The main machine is used for providing a freezing medium. The freezing catheter is used for transmitting the freezing medium. The main machine comprises an input port and an output port. Two ends of the freezing catheter are connected to the output port and the input port of the main machine respectively. The freezing head is in heat exchange connection with the freezing catheter. The freezing head is used for contacting the calculus or the bladder tumor. The freezing of the calculus can increase the brittleness of the calculus, and the efficiency of the lithotripsy is improved.

This invention provides a bladder tumor organoid, its culture method, and its applications, belonging to the field of organoid culture technology. The invention involves mixing bladder tumor tissue with a human bladder tumor organoid culture medium to obtain a cell suspension. This cell suspension is then cultured in an ultra-low adsorption cell culture plate to obtain bladder tumor organoids. This culture method utilizes an ultra-low adsorption cell culture plate, enabling the suspension culture of bladder tumor organoids in a liquid culture medium. The culture method described in this invention achieves rapid culture of human bladder tumor organoids, improving the culture success rate. Furthermore, the obtained human bladder tumor organoids can be digested and stably passaged.

Provided herein are methods and systems for detecting and monitoring cancer. The methods may include minimal residual disease analysis. The method may include using nucleic acids from a urine sample or a urine cell precipitate sample. The method may include determining nucleic acids in urine to detect a panel of biomarkers from a sample. The method may include monitoring the subject after transurethral bladder tumor resection.

The invention discloses a catheter connector for bladder tumor postoperative care. The catheter connector comprises a shunt tube and a locking clamp. The shunting pipe is fixedly arranged in the locking clamp; the device can meet multiple requirements of urination, drainage, flushing and medicine application at the same time through the integrated shunt tube, and the efficiency and convenience of postoperative care are greatly improved. By means of the integrated design, the trouble that multiple independent devices are needed in traditional nursing is reduced, and the complexity of nursing work is reduced. Due to the design of a locking clamp and a pressing roller in the device, stable connection with a common catheter connector is ensured. In addition, ball valves are arranged at the urination port and the drainage port, the channels can be closed when needed, accidental leakage of medicine or flushing fluid is prevented, meanwhile, the channels are allowed to be closed when liquid does not need to be collected, and inconvenience in the nursing process is reduced. The design of one-way valves at the tail ends of the flushing port and the medicine feeding port also prevents liquid from flowing back.

The invention belongs to the technical field of molecular biology and medical detection, and discloses a bladder cancer nucleic acid aptamer, a nucleic acid aptamer derivative and application thereof. The nucleotide sequence of the nucleic acid aptamer is as shown in SEQ ID NO: 6. A monoclonal nucleic acid aptamer DNA chain of a bladder cancer tissue sample is screened through an exponential enrichment systematic evolution (SELEX) technology, two target proteins in targeted combination with the nucleic acid aptamer are identified, and the nucleic acid aptamer can specifically target the target proteins CAPRIN1 and FXR1 on the surfaces of bladder tumor cells. The nucleic acid aptamer obtained through screening has the advantages of being high in affinity and specificity, free of immunogenicity, simple and stable in chemical synthesis, easy to store and mark and the like, and a new molecular tool is provided for early diagnosis and targeted therapy of bladder cancer.

This prostate treatment method includes an insertion step of inserting a balloon coated with a medicine into a urethra, an expansion step of expanding the balloon in a prostate part where the prostate is located in the urethra, and a step of injecting the medicine by piercing the prostate part with a microneedle attached to the surface of the balloon. This bladder tumor treatment method is for treating a bladder tumor having a tumor bulging part and a tumor bottom part, the bladder tumor treatment method being provided with a cutting step of cutting off the tumor bulging part, and a freezing step of freezing the tumor bottom part.

Recombinant BCG, a preparation method therefor and an application thereof. A shuttle plasmid that can express a FimH protein on the surface of BCG is constructed, and a gene fragment that expresses the FimH protein is transformed into wild-type BCG to thereby obtain recombinant BCG. Upon verification, the recombinant BCG can express the FimH protein on the surface of BCG; therefore, the BCG can specifically bind to subjects that can selectively bind to the FimH protein. The recombinant BCG can also enhance the local innate immune effect and adaptive immune effect induced by BCG and the anti-tumor effect of peripheral blood mononuclear cells, and also significantly improves the effect of BCG against bladder tumors, and is used to treat bladder tumors.